211 related articles for article (PubMed ID: 3813520)
1. Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.
Ariza J; Bosch J; Gudiol F; Liñares J; Viladrich PF; Martín R
Antimicrob Agents Chemother; 1986 Dec; 30(6):958-60. PubMed ID: 3813520
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial susceptibility of
Shevtsov A; Syzdykov M; Kuznetsov A; Shustov A; Shevtsova E; Berdimuratova K; Mukanov K; Ramankulov Y
Antimicrob Resist Infect Control; 2017; 6():130. PubMed ID: 29299304
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibilities of Brucella isolates from various clinical specimens.
Bayram Y; Korkoca H; Aypak C; Parlak M; Cikman A; Kilic S; Berktas M
Int J Med Sci; 2011 Mar; 8(3):198-202. PubMed ID: 21448305
[TBL] [Abstract][Full Text] [Related]
4. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Qatar between 2014 - 2015.
Deshmukh A; Hagen F; Sharabasi OA; Abraham M; Wilson G; Doiphode S; Maslamani MA; Meis JF
BMC Microbiol; 2015 Jun; 15():121. PubMed ID: 26073177
[TBL] [Abstract][Full Text] [Related]
5. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis.
Ariza J; Gudiol F; Pallarés R; Rufí G; Fernández-Viladrich P
Antimicrob Agents Chemother; 1985 Oct; 28(4):548-51. PubMed ID: 4073878
[TBL] [Abstract][Full Text] [Related]
6. Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load.
Vrioni G; Bourdakis A; Pappas G; Pitiriga V; Mavrouli M; Pournaras S; Tsakris A
Antimicrob Agents Chemother; 2014 Dec; 58(12):7541-4. PubMed ID: 25246401
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimicrobial susceptibility testing of human Brucella melitensis isolates from Ulanqab of Inner Mongolia, China.
Liu ZG; Di DD; Wang M; Liu RH; Zhao HY; Piao DR; Zhao ZZ; Hao YQ; Du YN; Jiang H; Cui BY; Xia XZ
BMC Infect Dis; 2018 Jan; 18(1):43. PubMed ID: 29338693
[TBL] [Abstract][Full Text] [Related]
8. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp.
Turan H; Arslan H; Azap OK; Serefhanoğlu K; Uncu H
Int J Antimicrob Agents; 2007 Aug; 30(2):186-7. PubMed ID: 17462865
[No Abstract] [Full Text] [Related]
9. In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance.
Abdel-Maksoud M; House B; Wasfy M; Abdel-Rahman B; Pimentel G; Roushdy G; Dueger E
Ann Clin Microbiol Antimicrob; 2012 Aug; 11():24. PubMed ID: 22929054
[TBL] [Abstract][Full Text] [Related]
10. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.
Solera J; Rodríguez-Zapata M; Geijo P; Largo J; Paulino J; Sáez L; Martínez-Alfaro E; Sánchez L; Sepulveda MA; Ruiz-Ribó MD
Antimicrob Agents Chemother; 1995 Sep; 39(9):2061-7. PubMed ID: 8540716
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole.
Gutiérrez Altés A; Díez Enciso M; Peña García P; Campos Bueno A
Antimicrob Agents Chemother; 1982 Mar; 21(3):501-3. PubMed ID: 6980624
[TBL] [Abstract][Full Text] [Related]
12. Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.
Lang R; Shasha B; Rubinstein E
Antimicrob Agents Chemother; 1993 Nov; 37(11):2333-6. PubMed ID: 8285615
[TBL] [Abstract][Full Text] [Related]
13. Early clinical response to different therapeutic regimens for human brucellosis.
Malik GM
Am J Trop Med Hyg; 1998 Feb; 58(2):190-1. PubMed ID: 9502602
[TBL] [Abstract][Full Text] [Related]
14. [E-test susceptibility results of brucella strains for streptomycin, rifampicin, ciprofloxacin and tetracycline].
Sengöz G; Yaşar KK; Kutlu SB; Durdu YB; Ozdemir R; Nazlican O
Mikrobiyol Bul; 2006 Jul; 40(3):265-8. PubMed ID: 17001857
[TBL] [Abstract][Full Text] [Related]
15. Rifampicin resistance in a strain of Brucella melitensis after treatment with doxycycline and rifampicin.
De Rautlin de la Roy YM; Grignon B; Grollier G; Coindreau MF; Becq-Giraudon B
J Antimicrob Chemother; 1986 Nov; 18(5):648-9. PubMed ID: 3804888
[No Abstract] [Full Text] [Related]
16. Comparison of five antimicrobial regimens for the treatment of brucellar spondylitis: a prospective, randomized study.
Bayindir Y; Sonmez E; Aladag A; Buyukberber N
J Chemother; 2003 Oct; 15(5):466-71. PubMed ID: 14598939
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility testing of Brucella melitensis isolated from patients with acute brucellosis in a centre of Iran.
Razzaghi R; Rastegar R; Momen-Heravi M; Erami M; Nazeri M
Indian J Med Microbiol; 2016; 34(3):342-5. PubMed ID: 27514957
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Diagnostic Aspects of Brucellosis and Antimicrobial Susceptibility of Brucella Isolates in Hamedan, Iran.
Torkaman Asadi F; Hashemi SH; Alikhani MY; Moghimbeigi A; Naseri Z
Jpn J Infect Dis; 2017 May; 70(3):235-238. PubMed ID: 27580575
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of in vitro activities of tigecycline and various antibiotics against Brucella spp.
Ozhak-Baysan B; Ongut G; Ogunc D; Gunseren F; Sepin-Ozen N; Ozturk F; Aktepe OC; Gultekin M
Pol J Microbiol; 2010; 59(1):55-60. PubMed ID: 20568531
[TBL] [Abstract][Full Text] [Related]
20. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial.
Hashemi SH; Gachkar L; Keramat F; Mamani M; Hajilooi M; Janbakhsh A; Majzoobi MM; Mahjub H
Int J Infect Dis; 2012 Apr; 16(4):e247-51. PubMed ID: 22296864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
